Table 3.
Univariate survival analysis of clinicopathological findings.
| Characteristic | Number | 3-year overall survival rate (%) | P | |
|---|---|---|---|---|
| Age (years) | 0.127 | |||
| ≤60 | 45 | 62.2 | ||
| >60 | 95 | 48.4 | ||
| Sex | 0.221 | |||
| Male | 117 | 51.3 | ||
| Female | 23 | 62.5 | ||
| Tumor location | 0.614 | |||
| Upper | 3 | 66.7 | ||
| Middle/lower | 137 | 52 | ||
| Differentiation | 0.018 | |||
| Well/moderate | 110 | 60 | ||
| Poor | 30 | 83.3 | ||
| pT | 0.018 | |||
| pT1/pT2 | 66 | 69.7 | ||
| pT3/pT4 | 74 | 50 | ||
| pN | <0.001 | |||
| pN0 | 63 | 76.2 | ||
| pN1–3 | 77 | 46.8 | ||
| TNM staging | <0.001 | |||
| I–II | 71 | 78.9 | ||
| III–IV | 69 | 40.6 | ||
| Lymphatic invasion | 0.027 | |||
| Negative | 63 | 66.7 | ||
| Positive | 77 | 48.1 | ||
| Venous invasion | 0.58 | |||
| Negative | 48 | 64.6 | ||
| Positive | 92 | 59.8 | ||
| CTCs | 0.013 | |||
| Negative | 78 | 70.5 | ||
| Positive | 62 | 50 | ||